Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant

Inclusion Criteria: * Patients with symptomatic active multiple myeloma who have completed autotransplant are eligible for the study; patients should be assessed for eligibility within 35 days of the transplant and treatment should commence within 10 weeks of the transplant * Performance status of 0-2 based on Southwest Oncology Group (SWOG) criteria; patients with a poor performance status (3-4) are also eligible, if complications of the bone such as compression fracture, hyperviscosity or infection such as pneumonia have been adequately treated * No significant co-morbid medical conditions; no uncontrolled life threatening infection * Unsupported platelet count \> 80,000/uL * Absolute neutrophil count (ANC) \> 1000/uL * Signed informed consent should be obtained from all patients in accordance with institutional and federal guidelines Exclusion Criteria: * Patients with a history of recent (\< 6 months) myocardial infarction, unstable angina, difficult to control congestive heart failure, uncontrolled hypertension, difficult to control significant cardiac arrhythmias, or arrhythmia associated with prolonged QT interval * Pregnant or nursing women; women of child-bearing potential must have a negative pregnancy documented within one week of registration; women/men of reproductive potential may not participate unless they have agreed to use two forms of effective contraceptive method * Patients with a grade 3-4 neuropathy related to prior exposure to bortezomib, thalidomide, or other agents * Human immunodeficiency virus (HIV) positive patients * Transaminases \> 2 x normal values * Bilirubin \> 2 x normal values * Active uncontrolled infection * History of significant psychiatric illness; steroid induced psychosis